This unveiled a marked cellular heterogeneity of genetic AML subtypes and revealed two distinct transcriptomic subtypes of NPM1-mutated AML with different immune evasion properties and response to hematopoietic stem cell transplantation; results with direct clinical implications for the treatment of patients with AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.